BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

6:29 PM
 | 
Oct 01, 2012
 |  BC Extra  |  Clinical News

Additional OS details for T-DM1

Roche (SIX:ROG; OTCQX:RHHBY) and its Genentech Inc. unit said T-DM1 led to median overall survival (OS) of 30.9 months vs. 25.1 months for Tykerb lapatinib plus Xeloda capecitabine in the Phase III EMILIA trial in second-line HER2-positive metastatic breast cancer (HR=0.68, p=0.0006). The companies had said in...

Read the full 240 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >